Merck + Co., Inc.

Other

Ashok V Katdare

Kenneth A Kramer

Simon R Bechard

Tzyy-Show H Chen

Thomas G Nyairo

Karen C Thompson

Udit Batra

Raymond J Higgins

Gerald S Brenner

Colin R Gardner

Drazen Ostovic

Christine Stelmach

Donna T Whiteford

Chung Y Lui

Joseph F Bavitz

Denise Pretzer

Scott N Kleinbart

This invention relates to a 50% drug loaded compressed tablet formulation for efavirenz. Efavirenz is a non-nucleoside reverse trancriptase inhibitor being studied clinically for use in the treatment of HIV infections and AIDS.

Compressed tablet formulation

Pharmaceutical compositions of bisphosphonic acids, and salts thereof, are prepared by wet granulation tablet formulation. These pharmaceutical compositions are useful in the treatment of disturbances involving calcium or phosphate metabolism, in particular, the treatment and prevention of diseases involving bone resorption, especially osteoporosis, Paget's disease, malignant hypercalcemia, and metastatic bone disease. These compositions are prepared without the addition of binder; instead, the drug itself acts as a binder.

Wet granulation formulation for bisphosphonic acids

This invention relates to a dry granulation capsule formulation of the HIV protease inhibitor, indinavir sulfate, which is useful in the treatment of AIDS, ARC or HIV infection. Processes for making the oral formulation are also disclosed.

Dry granulation formulation for an HIV protease inhibitor

The present invention relates to novel pharmaceutical tablets useful for administering pharmaceutical active ingredients, such as bisphosphonates. These tablets have improved surface properties which can aid esophageal transit, thereby reducing the potential for adverse gesture intestinal effects. The present invention also relates to processes for making said novel pharmaceutical tablets.

Pharmaceutical tablets

Pharmaceutical compositions of bisphosphonic acids, and salts thereof, are prepared by direct compression/dry mix tablet formulation. These pharmaceutical compositions are useful in the treatment of disturbances involving calcium or phosphate metabolism, in particular, the treatment and prevention of diseases involving bone resorption, especially osteoporosis, Paget's disease, malignant hypercalcemia, and metastatic bone disease.

Dry mix formulation for bisphosphonic acids

Tablet

An effervescent formulation of alendronate contains an acid source, a carbonate source, a binder, a lubricant and optionally, flavoring agents, colorants and sweeteners.

Effervescent alendronate formulation

Growing community of inventors

Norristown, PA, United States of America

Ashok V Katdare